Abstract Patients with suspected hereditary renal cell cancer (RCC) are under-referred for genetic evaluation. Characterizing the prevalence and characteristics of suspected inherited RCC is a crucial step toward advancing personalized, genetically-based cancer risk management for patients and their families. To evaluate the prevalence and characteristics of suspected inherited RCC syndromes based on consensus criteria, we performed a cross-sectional analysis of patients with a diagnosis of RCC in SEER (2001-2011, n = 105,754) and in our institutional cancer registry (2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013), n = 998). Consensus criteria for referral of patients with RCC for genetic evaluation from the American College of Medical Genetics and Genomics and National Society of Genetic Counselors (ACMG/NSGC) were applied to the two cohorts. The associations between meeting referral criteria with demographic characteristics were assessed with chisquare tests. Overall, 24.0 % of the SEER cohort and 33.7 % of our institutional cohort met ACMG/NSGC referral criteria for genetic counseling. While white patients more commonly met early onset clear cell RCC criteria, black patients met papillary RCC criteria at twice the rate of whites in both cohorts (p < 0.0001). As many as 1 in 5 individuals with RCC meet referral criteria for genetic evaluation based on newly emerging guidelines, with differences in pathology noted by race. Prospective genetic testing studies utilizing emerging referral guidelines should help to refine the genetic spectrum of inherited kidney cancer. This study supports efforts to increase awareness of referral of patients with RCC for genetic counseling particularly among urologic providers.
Introduction
Kidney cancer affects 338,000 individuals annually worldwide and accounts for approximately 143,000 deaths per year (Ferlay et al. 2015) . In the United States, kidney cancer ranks among the top ten leading cancers in annual incidence and mortality rate (Siegel et al. 2015) . Renal cell carcinoma (RCC) is the predominant type of kidney cancer that is derived from the renal tubular epithelium. RCC is comprised of a number of different histologically and genetically distinct types of cancer, each with a different clinical course and response to therapy. Clear cell RCC (ccRCC) is the most common histology, occurring in 75 % of kidney cancer cases. The other non-clear cell RCC histologies include papillary subtypes (10 %-15 %), chromophobe (3 %-5 %), collecting duct (1 %), and unclassified (1 %) (Störkel et al. 1997) . Most RCC cases are asymptomatic and found incidentally. The 5-year survival of patients with organ-confined disease versus those with distant metastases are strikingly different, 92 % vs. 12 %, respectively (Howlader et al. 2013) .
Multiple hereditary cancer syndromes have been welldescribed that include RCC of specific histologies. These include von Hippel-Lindau (VHL), hereditary papillary renal carcinoma (HPRC), Birt-Hogg-Dube (BHD), hereditary leiomyomatosis renal cell carcinoma (HLRCC), succinate dehydrogenase kidney cancer (SHD-RCC), tuberous sclerosis complex (TSC), and Cowden syndrome. The relationships between RCC histology, gene mutation, and inherited RCC syndrome are summarized in Table 1 (Benusiglio et al. 2014; Choyke et al. 1995; Kiuru et al. 2001; Lehtonen 2011; Linehan et al. 2010; Lonser et al. 2003; Pavlovich et al. 2002; Schmidt et al. 1999; Toro et al. 2008; Wei et al. 2006) .
Hereditary RCC is estimated to account for 5 % to 8 % of all newly diagnosed kidney cancers (Linehan et al. 2010) . While hereditary RCC syndromes have well-established cancerous and non-cancerous features, selection of patients with RCC for genetic evaluation and germline mutation testing is typically based upon meeting clinical criteria for the associated hereditary syndromes (Benusiglio et al. 2014; Choyke et al. 1995; Kiuru et al. 2001; Lehtonen 2011; Linehan et al. 2010; Lonser et al. 2003; Pavlovich et al. 2002; Schmidt et al. 1999; Toro et al. 2008; Wei et al. 2006) . At the present time, treating physicians are tasked with recognizing when a patient with RCC may be suspected of having an inherited predisposition and potentially benefit from a referral to genetic counseling. These referrals need to take into account the patient's age at RCC diagnosis, family history of cancer, histology, and specific clinical hallmarks of hereditary kidney cancer syndromes. However, this may lead to underreferral of patients with RCC to genetic counseling due to limited family history information, lack of time and knowledge among treating physicians regarding hereditary RCC, and lack of recognition of subtle clinical features associated with inherited syndromes. Therefore, the overall scope of patients with RCC who warrant referral for genetic evaluation for inherited risk may be under estimated.
Furthermore, in the current era of precision oncology, genetic counseling and knowledge of genetic predisposition are crucial to advance personalized cancer risk management and treatment which can have great impact for patients with RCC. Several targeted therapies are now available for patients with RCC, and studies incorporating germline mutations are expected to enhance options for treatment for these patients (ACS 2016). While guidelines do not currently exist for routine screening for kidney cancer, patients with hereditary kidney cancer syndromes identified through genetic testing or through a clinical diagnosis can consider screening and surveillance measures for early detection of cancers and conditions associated with the specific syndromes (Genetics of Kidney Cancer (Renal Cell Cancer)-Health Professional Version (PDQ®). Furthermore, while most recommendations for screening and surveillance are based upon expert opinion or consensus, patients with RCC and their families with hereditary kidney cancer syndromes can be provided with screening and surveillance options.
To estimate the overall prevalence of suspected inherited RCC that may warrant referral for genetic evaluation, we utilized recently published practice guidelines from the American College of Medical Genetics and Genomics (ACMG) and the National Society of Genetic Counselors (NSGC) (Hampel et al. 2015) and applied these referral criteria to the NCI SEER database (version November 2013) and our institutional cancer registry. We focused on referral criteria based on patient characteristics including tumor histology, bilaterality, and age at diagnosis since these are more readily available in clinical practice to determine referral, and since family history can be limited and is not captured in the SEER database. Prior studies have reported on racespecific differences in RCC histology (Chow et al. 2013; Olshan et al. 2013) . However, there are limited data regarding a focused application of genetic referral guidelines to RCC to identify the scope of suspected inherited RCC that warrant referral for genetic evaluation. (Hampel et al. 2015) . Additionally, those with clear cell RCC (8310/3) and either 1) age of diagnosis less than 50 years or 2) bilateral disease were also considered as Bmeeting referral criteria^ (Table 2 ) (Hampel et al. 2015) . SEER data were downloaded as ASCII text files from seer.cancer.gov. SAS 9.4 was used by the study statistician (SEH) to implement cohort selections based on inclusion/exclusion criteria. Similarly, data from our institutional cancer registry (Thomas Jefferson University Hospital [TJUH] ) from 2004 to 2013 were queried for kidney cancer cases using ICD-O-3 site code C64.9. The same histology code restrictions that were applied to the SEER data were applied to the TJUH data although no cases of collecting duct RCC exist in the TJUH data. The TJUH data do not contain information about multifocal or bilateral disease, so cases with clear cell RCC was determined to Bmeet referral criteria^only if age of diagnosis was less than 50 years. Data query was performed by TJUH cancer registry staff (F.G.). Additional exclusions were then performed in SAS by the study statistician.
Genetic Referral Guidelines Application
We applied the ACMG/NSGC practice guidelines to identify patients who may be referred for genetic evaluation for suspected hereditary RCC. The ACMG/NSGC recommend referral for genetic counseling for patients with kidney cancer who have (1) early-onset ccRCC histology, defined as age of diagnosis under 50 years, (2) ccRCC with at least one close relative with ccRCC; (3) bilateral or multifocal tumors, (4) papillary RCC, both type 1 and type 2 histology; (5) collecting duct RCC; (6) tubulopapillary RCC; or (7) RCC with BHDrelated histology including chromophobe, oncocytoma, or oncocytic hybrid (Hampel et al. 2015) . The ACMG/NSGC also suggest genetic counseling referral for patients with other suspected cancer syndromes that include kidney cancer, such as Lynch syndrome, Cowden syndrome, and tuberous sclerosis complex (TSC). We excluded Lynch syndrome from our analysis since patients with Lynch syndrome have urothelial carcinoma that involves the ureter and renal collecting ducts, which is outside the scope of our focus on RCC. The major diagnostic criteria of Cowden syndrome and TSC include non-malignant features such as macrocephaly and mucocutaneous lesions in Cowden syndrome, and connective tissue nevus and facial angiofibromas in TSC. We did not evaluate the prevalence of these hereditary cancer syndromes that include kidney cancer (Lynch syndrome, Cowden syndrome, and TSC) because there is no information or insufficient information on family history and non-malignant features in NCI SEER and our institutional cancer registry database to effectively identify potential patients to refer based on suspicion of these syndromes.
Data Analysis
Basic patient demographics-age of diagnosis, gender and race-were summarized for these patients in the entire sample as well by meeting referral criteria status. The associations between meeting referral criteria and demographic characteristics were assessed via chi-square tests. The relationship of race to referral criteria was further explored by testing the association of specific histologic criteria with race also using the chi-square test. Separate, parallel analyses were performed on the SEER and TJUH datasets. All analyses were performed in SAS 9.4 (SAS Institute Inc., Cary, NC). This project was approved by the Institutional Review Board at Thomas Jefferson University.
Results
Descriptive Characteristics A total of 105,754 records with specific kidney cancer site codes in NCI SEER (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) were included in the analysis after specified exclusions (Fig. 1) . At TJUH, 998 patients with a diagnosis of kidney cancer were treated between 2004 and 2013.
Patient demographics by meeting genetic referral criteria are shown in Table 3 . The cohorts were similar with respect to gender, with 62.9 % male and 37.1 % female in the NCI SEER database, and 62.3 % male and 37.7 % female in the TJUH database. The cohorts differed with respect to age and racial distributions, with the institutional cohort having slightly younger age at RCC diagnosis (mean age 61.0 years vs. 63.1 years, p < 0.001) and a larger proportion of black patients (20.4 % vs. 11.0 %, p < 0.001).
Meeting Referral Criteria Overall 24.0 % and 33.7 % of the kidney cancer cases included in the analyses met ACMG/ NSGC genetic referral criteria in the SEER and TJUH databases, respectively (Table 3 ). In the SEER data, 22.7 % of whites, 35.3 % of blacks and 21.6 % of individuals of other races met referral criteria. In the TJUH data, 29.7 % of whites, 48.5 % of blacks and 35.3 % of other races met referral criteria. This association between meeting referral criteria and race was significant in both datasets (p < 0.001). In the SEER data, sex was also significantly associated with meeting referral criteria (25.8 % men vs. 20.9 % women, p < 0.001). A similar magnitude of difference was seen in the TJUH data; however, the association was not significant (35.7 % men vs. 30.3 % women, p = 0.082).
A significant difference in distribution of pathologic referral criteria was noted by race (Table 4) . Among black patients, the most frequent referral criteria was papillary RCC (65.9 % in SEER, 69.7 % in TJUH), while whites met this criteria 39.1 % and 44.6 % of the time in SEER and TJUH, respectively (p < 0.001). Whites met ccRCC referral criteria at approximately twice the rate as blacks in the SEER dataset (39.3 % vs. 16.7 %, respectively; χ 2 (df) = 1312.8 (6), p < 0.001) and in the TJUH database (35.5 % vs. 16.2 %, respectively; χ 2 (df) = 18.4 (2), p < 0.001).
Discussion
The identification of patients for genetic counseling and genetic testing for germline mutations predisposing to RCC provides the opportunity to define the frequency of specific gene mutations in suspected hereditary cases, with personalized cancer risk management impacting patients and their families. The implications of identifying germline mutations are important not only for close relatives at risk for familial RCC, but also for the proband who is generally placed at increased risk of metachronous RCC tumors and risk of other extra-renal tumors. Emerging guidelines recommend a targeted approach to refer patients for genetic evaluation who have suspected hereditary RCC (Hampel et al. 2015; Reaume et al. 2013) These guidelines prioritize patients with a personal or family history of hereditary RCC syndromes, those with apparent non-syndromic tumors with multiple or bilateral presentation, (Table 1 and Table 2 ) (Hampel et al. 2015) . This study is the largest study to date focused on applying consensus guidelines for referral to genetic evaluation in the context of suspected inherited RCC, and characterizing the prevalence and characteristics of these patients meeting referral criteria. We applied the ACMG/NSGC guidelines to patients with kidney cancer in the NCI SEER database and our institutional kidney cancer registry to evaluate the prevalence of patients who would meet genetic counseling criteria to gain greater insight about the potential scope of patients who might benefit from germline genetic testing. Using targeted referral criteria, an estimated 24.0 % to 33.7 % of patients would qualify for genetic evaluation based strictly on RCC histologic subtypes. In a high volume center like our institution, where over 100 patients underwent surgical resection for kidney cancer per year, approximately 20 to 25 patients would be recommended for genetic evaluation of familial kidney cancer annually based on emerging professional guidelines.
We further evaluated race-specific differences in meeting genetic evaluation referral criteria. While the majority of patients with RCC are white, significant differences in meeting histologic criteria for referral to genetic counseling were found by race. Specifically, clear cell RCC, including early-onset and bilateral disease, was more commonly observed in white patients. On the other hand, non-clear cell RCC (papillary, collecting duct, and chromophobe subtypes) was more commonly observed in black patients. Race-specific differences in RCC histology have been reported previously (Chow et al. 2013; Olshan et al. 2013; Kara et al. 2016 ). Our analysis of applying ACMG/NSGC referral criteria to the SEER dataset and validation in our institutional dataset confirms prior reports of race-specific differences in kidney cancer pathology even when the focus is on genetic referral and helps to better refine estimates of referral to genetic counseling. Given that race was ascertained by self-report, a re-evaluation of referral criteria incorporating genetic ancestry may lead to further refinement of the proportion of patients with RCC that may warrant referral for genetic evaluation.
The identification of hereditary RCC can have clinical management implications for patients and their families. Screening for kidney cancer and other cancers/conditions associated with specific syndromic genetic mutations are options for patients and supported by expert opinion or consensus, though data on RCC mortality benefit are not currently available (Genetics of Kidney Cancer (Renal Cell Cancer)-Health Professional Version (PDQ®). However, experience in other hereditary cancer syndromes such as Hereditary Breast and Ovarian Cancer or Lynch syndrome shows that identification of families suspected of inherited cancer risk and genetic testing is given Tier 1 status by the CDC (highest level of evidence for clinical benefit), and impacts cancer risk management as per the National Comprehensive Cancer Network (NCCN) (CDC Genomic Application ToolKit; NCCN Clinical Practice Guidelines). Thus, genetic testing experience in other hereditary cancer syndromes indicates that risk management specific to hereditary RCC is likely to be effective and warrants further study.
Study Limitations
This study has some limitations. The point estimate of prevalence of patients with RCC meeting referral criteria may have been influenced by the inclusion and exclusion criteria for our analyses, which were affected by lack of family history data in the SEER dataset and limited information of bilateral disease in the TJU cohort. Our analyses were based on selected histologic subtypes that have been shown to be associated with established hereditary cancer syndromes. We were not able to take into consideration family history or other clinical manifestations, which are known to be important criteria in identifying patients with familial disease due to lack of family history data in both SEER and our institutional cancer registry. This limitation in family history data and other clinical manifestations in the NCI SEER dataset and our institutional cancer registry reflects real world clinical practice as well. Another limitation is the exclusion of smoking history in our analysis because the data were not available on both NCI SEER and our institutional cancer registries. Smoking has been shown to be an independent risk factor for clear cell and papillary RCC (Patel et al. 2015) . Smoking history needs to be included in the risk analysis of patients with suspected hereditary kidney cancer.
The third limitation stems from the fact that the actual presence of germline mutations was not able to be reported here to correspond with our results. The purpose of our study was to apply genetic referral guidelines to two large patient cohorts to determine the scope of patients who meet criteria for genetic counseling. As DNA is not collected as part of SEER or our institutional cancer registry, correlating mutation data is not possible. However, our study serves as the foundation for a future prospective genetic testing study that focuses on targeted genetic testing and mutation analysis to determine germline mutations rates and correlation to patient cancer features (such as age at diagnosis, pathology, and family cancer history) for major impact in genetic evaluation for suspected inherited RCC. Such studies need a basis of knowledge of the prevalence of suspected inherited cancer susceptibility, which our study has uncovered in two large patient cohorts.
Practice Implications
Our study uncovered that 1 in 5 patients with kidney cancer met genetic referral criteria proposed by ACMG/NSGC, which is under-appreciated among oncology providers and particularly among urologic providers. Our data support efforts to raise awareness in the oncologic community of the need to refer patients with RCC meeting referral criteria for genetic counseling to determine if genetic testing is appropriate based on factoring in family cancer history and patient preferences. While these criteria may be refined in the future, implementation of these guidelines will likely lead to increased referral volumes to clinical genetics practices which may warrant consideration of additional resources (particularly staff with expertise in hereditary kidney cancer syndromes) to meet the demand for genetic evaluation. Referring clinicians will also need programs and approaches to identify patients with RCC for referral for genetic evaluation. Potential strategies could include optimizing electronic medical records to automate referral criteria to alert for best practice and establish routine intake of family history for patients with RCC. In the current era of multigene panel testing, genetic testing for suspected inherited kidney cancer could uncover a spectrum of germline mutations that were previously unknown but could have significant cancer risk, cancer surveillance, and treatment implications for patients and their families. Without a referral stream, such discoveries will remain limited for patients with RCC highlighting the need for greater awareness among clinicians to refer patients with RCC meeting criteria for genetic counseling. Further study of these findings is warranted and points to the need for identifying and referring patients with RCC for genetic evaluation.
Research Recommendation
While the current literature reports that 5 % of RCC is inherited (Linehan et al. 2010) , our study after applying emerging genetic referral guidelines, shows that approximately 20 % of patients with RCC will warrant referral for genetic evaluation to identify the subset with inherited predisposition. Prospective clinical genetic testing studies are needed to refine the referral criteria for patients with suspected hereditary cancer syndromes and further define the genetic spectrum predisposing to inherited RCC risk.
Conclusion
Our study has revealed that approximately 24-33 % of patients with RCC warrant referral for genetic evaluation based on age at diagnosis and histologic criteria proposed by the ACMG/NSGC. Providers need to have increased awareness of recognizing which patients may warrant referral for genetic counseling. Prospective genetic testing studies are needed to refine the evolving guidelines to advance personalized cancer risk management and treatment for patients with inherited RCC.
